哮喘相关信号通路的研究现状  

Research Status of Asthma Related Signaling Pathways

作　　者：石慧莉 杨一民[2] 王珊珊[1] 范海婷 李溦 黄永莲 SHI Hui-li;YANG Yi-min;WANG Shan-shan;FAN Hai-ting;LI Wei;HUANG Yong-lian(The Second Clinical Medical College of Fujian University of Traditional Chinese Medicine,Fuzhou 350122,Fujian,China;Department of Pediatrics,Xiamen Hospital of Traditional Chinese Medicine,Fujian University of Traditional Chinese Medicine,Xiamen 361009,Fujian,China)

机构地区：[1]福建中医药大学第二临床医学院,福建福州350122 [2]福建中医药大学附属厦门市中医院儿科,福建厦门361009

出　　处：《医学信息》2022年第1期50-53,共4页Journal of Medical Information

基　　金：福建省科技局引导性项目(编号:2019D012)。

摘　　要：细胞因子可作为评估哮喘严重程度的标志物,可参与信号通路信息的表达与调控,而信号通路又成为炎症发生的调节器,能够诱导炎症介质参与哮喘的发生,亦可通过抑制剂降低炎症介质的表达,抑制炎症反应,减轻气道高反应性,进而减缓气道重塑。本文主要对STAT通路、NF-κB通路、MAPK通路,3个与哮喘密切相关的经典信号通路的研究现状进行综述,以期指导临床用药。Cytokines can be used as markers of the severity of asthma,and can be involved in the expression and regulation of signaling pathway information.The signaling pathway has become a regulator of inflammation,which can induce inflammatory mediators to participate in the occurrence of asthma.Inhibitors can also reduce the expression of inflammatory mediators,inhibit inflammatory reactions,reduce airway hyperresponsiveness,and thus slow down airway remodeling.This paper mainly reviews the research status of classical signaling pathways closely related to asthma in STAT pathway,NF-κB pathway and MAPK pathway,in order to guide clinical medication.

关 键 词：信号通路 哮喘 细胞因子 炎症反应 

分 类 号：R562[医药卫生—呼吸系统] R563[医药卫生—内科学]